AstraZeneca boss criticises UK public health body's decision to block breast cancer treatment for NHS use

The National Institute for Health and Care Excellence (NICE) decided in March this year that patients should be denied access to Enhertu because it said the drug did not provide value for money.

Friday 26 July 2024 12:14, UK

Please use Chrome browser for a more accessible video player

The chief executive of AstraZeneca has criticised a public health body for refusing to make one of its breast cancer treatments available to NHS patients in England and Wales.
Why you can trust Leading wesley

Watch Next